COVID-19 Vaccine Events FDA 
Healthcare IT Today
SEPTEMBER 20, 2024
The following is a guest article by Jay Nakashima, President at eHealth Exchange An FDA project aims to make it as easy as possible for clinicians to report adverse drug events and share important clinical data with public health agencies to investigate the event.
Healthcare IT Today
SEPTEMBER 21, 2024
Read more… FDA FHIR Pilot Automates Adverse Events Reporting and Validation. Jay Nakashima at eHealth Exchange detailed how California’s Cedars-Sinai used FHIR to send adverse events related to COVID-19 vaccines to the FDA – a process that replaced manual data entry and faxing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
HIT Consultant
NOVEMBER 30, 2021
Labcorp (NYSE: LH) is now offering observed self-collection for COVID-19 PCR testing in more than 500 of its patient service centers (PSCs) nationwide for people without symptoms or known exposure. Food and Drug Administration (FDA), and worked with companies to develop COVID-19 vaccines and therapies.
Health Populi
JUNE 24, 2021
Translation: watch out for winter and flu season, especially if people don’t re-mask and take care to protect themselves and others — particularly important in geographies where more folks have opted out of getting vaccinated. We also expect innovation to come out of pharma and biotech labs, and who will pay for new-new therapies?
Dot Compliance
FEBRUARY 1, 2022
The race to develop a COVID-19 vaccine highlighted the power of artificial intelligence (AI) and machine learning (ML) as Johnson & Johnson, Moderna and Pfizer employed these technologies to swiftly get their vaccines to market. The next evolution is for companies to implement Industry 4.0 References. References.
SQA
MARCH 25, 2021
United States Food and Drug Administration (FDA) – Regulations and Guidances for Biologics and the Bioresearch Monitoring Program (BIMO). Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency, January 2021.
SQA
JUNE 10, 2021
The report summarizes the main activities of the year, such as general and normative publications, regulatory projects, community participation events, and innovations implemented. Backgrounder – Government of Canada Investments in Biomanufacturing, Development of COVID-19 Vaccines and Therapeutics, and Research, 18 May 2021.
Expert insights. Personalized for you.
119 
Let's personalize your content